|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's range||148.46 - 148.96|
|52-week range||120.40 - 174.16|
|Beta (5Y monthly)||1.01|
|PE ratio (TTM)||14.58|
|Earnings date||01 Feb 2023 - 06 Feb 2023|
|Forward dividend & yield||2.64 (1.77%)|
|Ex-dividend date||17 Jan 2023|
|1y target est||143.07|
LA JOLLA, Calif. & PHOENIX, November 15, 2022--DermTech, Inc. (NASDAQ: DMTK) ("DermTech" or the "Company"), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today an agreement with Sonora Quest Laboratories (Sonora Quest), Arizona’s leading diagnostic laboratory, to expand access to enhanced melanoma detection. As a result of the agreement, Sonora Quest will be the exclusive laboratory in Arizona to offer the DermTech Melanoma Test to its vast network
NORTHAMPTON, MA / ACCESSWIRE / November 8, 2022 / Quest Diagnostics Healthy NewsWorks Healthy NewsWorks (HNW) empowers elementary and middle-school students to advocate for health literacy through school-based journalism programs. HNW provides ...
Quest Diagnostics (NYSE:DGX), the world's leading provider of diagnostic information services, today announced that Jim Davis has succeeded Steve Rusckowski as the CEO and President of Quest Diagnostics, completing a transition first announced on February 3, 2022.